BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24602611)

  • 21. CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1.
    Su S; Xu H; Chen X; Qiao G; Farooqi AA; Tian Y; Yuan R; Liu X; Li C; Li X; Wu N; Lin X
    Recent Pat Anticancer Drug Discov; 2018; 13(3):360-367. PubMed ID: 29956637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification of native alpha-enolase from Streptococcus pneumoniae that binds plasminogen and is immunogenic.
    Whiting GC; Evans JT; Patel S; Gillespie SH
    J Med Microbiol; 2002 Oct; 51(10):837-843. PubMed ID: 12435062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
    Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
    Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
    Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
    World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
    Dutta S; Bandyopadhyay C; Bottero V; Veettil MV; Wilson L; Pins MR; Johnson KE; Warshall C; Chandran B
    Mol Oncol; 2014 May; 8(3):483-507. PubMed ID: 24457100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of Candida albicans enolase to plasmin(ogen) results in enhanced invasion of human brain microvascular endothelial cells.
    Jong AY; Chen SHM; Stins MF; Kim KS; Tuan TL; Huang SH
    J Med Microbiol; 2003 Aug; 52(Pt 8):615-622. PubMed ID: 12867553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V; Whawell SA; Werner F; Deadman JJ
    Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein.
    Andronicos NM; Ranson M; Bognacki J; Baker MS
    Biochim Biophys Acta; 1997 Jan; 1337(1):27-39. PubMed ID: 9003434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of the carnosine-gallic acid synthetic peptide on MMP-2 and MMP-9 in human fibrosarcoma HT1080 cells.
    Kim SR; Eom TK; Byun HG
    J Pept Sci; 2014 Sep; 20(9):716-24. PubMed ID: 24956509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. alpha-Enolase binds to human plasminogen on the surface of Bacillus anthracis.
    Agarwal S; Kulshreshtha P; Bambah Mukku D; Bhatnagar R
    Biochim Biophys Acta; 2008; 1784(7-8):986-94. PubMed ID: 18456007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
    Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
    Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enolase as a plasminogen binding protein in Leishmania mexicana.
    Vanegas G; Quiñones W; Carrasco-López C; Concepción JL; Albericio F; Avilán L
    Parasitol Res; 2007 Nov; 101(6):1511-6. PubMed ID: 17653767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Requirement of plasminogen binding to its cell-surface receptor α-enolase for efficient regeneration of normal and dystrophic skeletal muscle.
    Díaz-Ramos À; Roig-Borrellas A; García-Melero A; Llorens A; López-Alemany R
    PLoS One; 2012; 7(12):e50477. PubMed ID: 23239981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
    Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
    Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.